DD208811A5 - Verfahren zur herstellung von gewebsthromboplastin - Google Patents

Verfahren zur herstellung von gewebsthromboplastin Download PDF

Info

Publication number: DD208811A5
Authority: DD; German Democratic Republic
Prior art keywords: thromboplastin; factor vii; extraction; tissue; calcium
Prior art date: 1981-12-21

Application number

DD82246077A

Other languages

German (de)

English (en)

Inventor

Udo Becker

Eugen Schaich

Manfred Weigert

Original Assignee

Boehringer Mannheim Gmbh

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1981-12-21

Filing date

1982-12-16

Publication date

1984-04-11

1982-12-16 Application filed by Boehringer Mannheim Gmbh filed Critical Boehringer Mannheim Gmbh

1984-04-11 Publication of DD208811A5 publication Critical patent/DD208811A5/de

Links

238000000034 method Methods 0.000 title claims description 18
238000004519 manufacturing process Methods 0.000 title claims description 4
108010000499 Thromboplastin Proteins 0.000 claims abstract description 39
102000002262 Thromboplastin Human genes 0.000 claims abstract description 39
108010023321 Factor VII Proteins 0.000 claims abstract description 31
102100023804 Coagulation factor VII Human genes 0.000 claims abstract description 28
238000000605 extraction Methods 0.000 claims abstract description 21
CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 claims abstract description 14
238000002360 preparation method Methods 0.000 claims abstract description 14
229910001424 calcium ion Inorganic materials 0.000 claims abstract description 13
BHPQYMZQTOCNFJ-UHFFFAOYSA-N Calcium cation Chemical compound [Ca+2] BHPQYMZQTOCNFJ-UHFFFAOYSA-N 0.000 claims abstract description 11
239000000284 extract Substances 0.000 claims abstract description 10
239000004094 surface-active agent Substances 0.000 claims abstract description 9
239000000843 powder Substances 0.000 claims abstract description 8
239000012266 salt solution Substances 0.000 claims abstract description 6
229940105772 coagulation factor vii Drugs 0.000 claims abstract description 4
PGOHTUIFYSHAQG-LJSDBVFPSA-N (2S)-6-amino-2-[[(2S)-5-amino-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-4-amino-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-5-amino-2-[[(2S)-5-amino-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S,3R)-2-[[(2S)-5-amino-2-[[(2S)-2-[[(2S)-2-[[(2S,3R)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-5-amino-2-[[(2S)-1-[(2S,3R)-2-[[(2S)-2-[[(2S)-2-[[(2R)-2-[[(2S)-2-[[(2S)-2-[[2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-1-[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-amino-4-methylsulfanylbutanoyl]amino]-3-(1H-indol-3-yl)propanoyl]amino]-5-carbamimidamidopentanoyl]amino]propanoyl]pyrrolidine-2-carbonyl]amino]-3-methylbutanoyl]amino]-4-methylpentanoyl]amino]-4-methylpentanoyl]amino]acetyl]amino]-3-hydroxypropanoyl]amino]-4-methylpentanoyl]amino]-3-sulfanylpropanoyl]amino]-4-methylsulfanylbutanoyl]amino]-5-carbamimidamidopentanoyl]amino]-3-hydroxybutanoyl]pyrrolidine-2-carbonyl]amino]-5-oxopentanoyl]amino]-3-hydroxypropanoyl]amino]-3-hydroxypropanoyl]amino]-3-(1H-imidazol-5-yl)propanoyl]amino]-4-methylpentanoyl]amino]-3-hydroxybutanoyl]amino]-3-(1H-indol-3-yl)propanoyl]amino]-5-carbamimidamidopentanoyl]amino]-5-oxopentanoyl]amino]-3-hydroxybutanoyl]amino]-3-hydroxypropanoyl]amino]-3-carboxypropanoyl]amino]-3-hydroxypropanoyl]amino]-5-oxopentanoyl]amino]-5-oxopentanoyl]amino]-3-phenylpropanoyl]amino]-5-carbamimidamidopentanoyl]amino]-3-methylbutanoyl]amino]-4-methylpentanoyl]amino]-4-oxobutanoyl]amino]-5-carbamimidamidopentanoyl]amino]-3-(1H-indol-3-yl)propanoyl]amino]-4-carboxybutanoyl]amino]-5-oxopentanoyl]amino]hexanoic acid Chemical compound CSCC[C@H](N)C(=O)N[C@@H](Cc1c[nH]c2ccccc12)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C)C(=O)N1CCC[C@H]1C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(=O)NCC(=O)N[C@@H](CO)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CS)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H]([C@@H](C)O)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CO)C(=O)N[C@@H](CO)C(=O)N[C@@H](Cc1cnc[nH]1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](Cc1c[nH]c2ccccc12)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](Cc1ccccc1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](Cc1c[nH]c2ccccc12)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCCCN)C(O)=O PGOHTUIFYSHAQG-LJSDBVFPSA-N 0.000 claims description 35
229940012413 factor vii Drugs 0.000 claims description 27
230000035945 sensitivity Effects 0.000 claims description 18
239000000243 solution Substances 0.000 claims description 10
159000000007 calcium salts Chemical class 0.000 claims description 9
FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 claims description 7
230000023555 blood coagulation Effects 0.000 claims description 4
239000003153 chemical reaction reagent Substances 0.000 claims description 4
102000016519 Coagulation factor VII Human genes 0.000 claims description 3
239000007853 buffer solution Substances 0.000 claims description 2
150000001732 carboxylic acid derivatives Chemical class 0.000 claims description 2
235000013311 vegetables Nutrition 0.000 claims 1
210000002381 plasma Anatomy 0.000 description 27
210000001519 tissue Anatomy 0.000 description 13
230000002950 deficient Effects 0.000 description 10
206010053567 Coagulopathies Diseases 0.000 description 9
239000011575 calcium Substances 0.000 description 9
230000035602 clotting Effects 0.000 description 8
OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 7
229910052791 calcium Inorganic materials 0.000 description 7
230000015271 coagulation Effects 0.000 description 6
238000005345 coagulation Methods 0.000 description 6
238000005406 washing Methods 0.000 description 5
102000015081 Blood Coagulation Factors Human genes 0.000 description 4
108010039209 Blood Coagulation Factors Proteins 0.000 description 4
108010094028 Prothrombin Proteins 0.000 description 4
TZCXTZWJZNENPQ-UHFFFAOYSA-L barium sulfate Chemical compound [Ba+2].[O-]S([O-])(=O)=O TZCXTZWJZNENPQ-UHFFFAOYSA-L 0.000 description 4
239000003114 blood coagulation factor Substances 0.000 description 4
150000003839 salts Chemical class 0.000 description 4
239000000725 suspension Substances 0.000 description 4
AZUYLZMQTIKGSC-UHFFFAOYSA-N 1-[6-[4-(5-chloro-6-methyl-1H-indazol-4-yl)-5-methyl-3-(1-methylindazol-5-yl)pyrazol-1-yl]-2-azaspiro[3.3]heptan-2-yl]prop-2-en-1-one Chemical compound ClC=1C(=C2C=NNC2=CC=1C)C=1C(=NN(C=1C)C1CC2(CN(C2)C(C=C)=O)C1)C=1C=C2C=NN(C2=CC=1)C AZUYLZMQTIKGSC-UHFFFAOYSA-N 0.000 description 3
QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 3
206010010356 Congenital anomaly Diseases 0.000 description 3
230000015572 biosynthetic process Effects 0.000 description 3
230000006378 damage Effects 0.000 description 3
230000000694 effects Effects 0.000 description 3
239000002244 precipitate Substances 0.000 description 3
DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 2
102100027378 Prothrombin Human genes 0.000 description 2
108090000190 Thrombin Proteins 0.000 description 2
208000007536 Thrombosis Diseases 0.000 description 2
125000000129 anionic group Chemical group 0.000 description 2
239000003945 anionic surfactant Substances 0.000 description 2
210000004369 blood Anatomy 0.000 description 2
239000008280 blood Substances 0.000 description 2
239000000872 buffer Substances 0.000 description 2
125000002091 cationic group Chemical group 0.000 description 2
AGVAZMGAQJOSFJ-WZHZPDAFSA-M cobalt(2+);[(2r,3s,4r,5s)-5-(5,6-dimethylbenzimidazol-1-yl)-4-hydroxy-2-(hydroxymethyl)oxolan-3-yl] [(2r)-1-[3-[(1r,2r,3r,4z,7s,9z,12s,13s,14z,17s,18s,19r)-2,13,18-tris(2-amino-2-oxoethyl)-7,12,17-tris(3-amino-3-oxopropyl)-3,5,8,8,13,15,18,19-octamethyl-2 Chemical compound [Co+2].N#[C-].[N-]([C@@H]1[C@H](CC(N)=O)[C@@]2(C)CCC(=O)NC[C@@H](C)OP(O)(=O)O[C@H]3[C@H]([C@H](O[C@@H]3CO)N3C4=CC(C)=C(C)C=C4N=C3)O)\C2=C(C)/C([C@H](C\2(C)C)CCC(N)=O)=N/C/2=C\C([C@H]([C@@]/2(CC(N)=O)C)CCC(N)=O)=N\C\2=C(C)/C2=N[C@]1(C)[C@@](C)(CC(N)=O)[C@@H]2CCC(N)=O AGVAZMGAQJOSFJ-WZHZPDAFSA-M 0.000 description 2
KXGVEGMKQFWNSR-UHFFFAOYSA-N deoxycholic acid Natural products C1CC2CC(O)CCC2(C)C2C1C1CCC(C(CCC(O)=O)C)C1(C)C(O)C2 KXGVEGMKQFWNSR-UHFFFAOYSA-N 0.000 description 2
201000007386 factor VII deficiency Diseases 0.000 description 2
BDAGIHXWWSANSR-UHFFFAOYSA-N methanoic acid Natural products OC=O BDAGIHXWWSANSR-UHFFFAOYSA-N 0.000 description 2
230000007935 neutral effect Effects 0.000 description 2
239000002736 nonionic surfactant Substances 0.000 description 2
229940039716 prothrombin Drugs 0.000 description 2
239000007974 sodium acetate buffer Substances 0.000 description 2
239000006228 supernatant Substances 0.000 description 2
229960004072 thrombin Drugs 0.000 description 2
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
HSINOMROUCMIEA-FGVHQWLLSA-N (2s,4r)-4-[(3r,5s,6r,7r,8s,9s,10s,13r,14s,17r)-6-ethyl-3,7-dihydroxy-10,13-dimethyl-2,3,4,5,6,7,8,9,11,12,14,15,16,17-tetradecahydro-1h-cyclopenta[a]phenanthren-17-yl]-2-methylpentanoic acid Chemical group C([C@@]12C)C[C@@H](O)C[C@H]1[C@@H](CC)[C@@H](O)[C@@H]1[C@@H]2CC[C@]2(C)[C@@H]([C@H](C)C[C@H](C)C(O)=O)CC[C@H]21 HSINOMROUCMIEA-FGVHQWLLSA-N 0.000 description 1
BHQCQFFYRZLCQQ-UHFFFAOYSA-N (3alpha,5alpha,7alpha,12alpha)-3,7,12-trihydroxy-cholan-24-oic acid Natural products OC1CC2CC(O)CCC2(C)C2C1C1CCC(C(CCC(O)=O)C)C1(C)C(O)C2 BHQCQFFYRZLCQQ-UHFFFAOYSA-N 0.000 description 1
OSWFIVFLDKOXQC-UHFFFAOYSA-N 4-(3-methoxyphenyl)aniline Chemical compound COC1=CC=CC(C=2C=CC(N)=CC=2)=C1 OSWFIVFLDKOXQC-UHFFFAOYSA-N 0.000 description 1
208000000412 Avitaminosis Diseases 0.000 description 1
CBOCVOKPQGJKKJ-UHFFFAOYSA-L Calcium formate Chemical compound [Ca+2].[O-]C=O.[O-]C=O CBOCVOKPQGJKKJ-UHFFFAOYSA-L 0.000 description 1
241000282472 Canis lupus familiaris Species 0.000 description 1
LZZYPRNAOMGNLH-UHFFFAOYSA-M Cetrimonium bromide Chemical compound [Br-].CCCCCCCCCCCCCCCC[N+](C)(C)C LZZYPRNAOMGNLH-UHFFFAOYSA-M 0.000 description 1
239000004380 Cholic acid Substances 0.000 description 1
108090000790 Enzymes Proteins 0.000 description 1
102000004190 Enzymes Human genes 0.000 description 1
108010014172 Factor V Proteins 0.000 description 1
108010014173 Factor X Proteins 0.000 description 1
102000009123 Fibrin Human genes 0.000 description 1
108010073385 Fibrin Proteins 0.000 description 1
BWGVNKXGVNDBDI-UHFFFAOYSA-N Fibrin monomer Chemical compound CNC(=O)CNC(=O)CN BWGVNKXGVNDBDI-UHFFFAOYSA-N 0.000 description 1
108010049003 Fibrinogen Proteins 0.000 description 1
102000008946 Fibrinogen Human genes 0.000 description 1
BDAGIHXWWSANSR-UHFFFAOYSA-M Formate Chemical compound [O-]C=O BDAGIHXWWSANSR-UHFFFAOYSA-M 0.000 description 1
239000004471 Glycine Substances 0.000 description 1
102000001554 Hemoglobins Human genes 0.000 description 1
108010054147 Hemoglobins Proteins 0.000 description 1
206010021135 Hypovitaminosis Diseases 0.000 description 1
DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
241001465754 Metazoa Species 0.000 description 1
229920003171 Poly (ethylene oxide) Polymers 0.000 description 1
208000024248 Vascular System injury Diseases 0.000 description 1
208000012339 Vascular injury Diseases 0.000 description 1
208000027418 Wounds and injury Diseases 0.000 description 1
239000008351 acetate buffer Substances 0.000 description 1
239000000654 additive Substances 0.000 description 1
230000000996 additive effect Effects 0.000 description 1
150000008044 alkali metal hydroxides Chemical class 0.000 description 1
125000000217 alkyl group Chemical group 0.000 description 1
239000003146 anticoagulant agent Substances 0.000 description 1
125000003118 aryl group Chemical group 0.000 description 1
238000003556 assay Methods 0.000 description 1
208000015294 blood coagulation disease Diseases 0.000 description 1
210000004556 brain Anatomy 0.000 description 1
239000004281 calcium formate Substances 0.000 description 1
229940044172 calcium formate Drugs 0.000 description 1
235000019255 calcium formate Nutrition 0.000 description 1
239000003093 cationic surfactant Substances 0.000 description 1
238000005119 centrifugation Methods 0.000 description 1
239000003795 chemical substances by application Substances 0.000 description 1
BHQCQFFYRZLCQQ-OELDTZBJSA-N cholic acid Chemical compound C([C@H]1C[C@H]2O)[C@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@@H](CCC(O)=O)C)[C@@]2(C)[C@@H](O)C1 BHQCQFFYRZLCQQ-OELDTZBJSA-N 0.000 description 1
229960002471 cholic acid Drugs 0.000 description 1
235000019416 cholic acid Nutrition 0.000 description 1
208000019425 cirrhosis of liver Diseases 0.000 description 1
230000009852 coagulant defect Effects 0.000 description 1
208000019060 congenital factor VII deficiency Diseases 0.000 description 1
239000000470 constituent Substances 0.000 description 1
239000000356 contaminant Substances 0.000 description 1
150000001893 coumarin derivatives Chemical class 0.000 description 1
230000007547 defect Effects 0.000 description 1
230000007812 deficiency Effects 0.000 description 1
KXGVEGMKQFWNSR-LLQZFEROSA-N deoxycholic acid Chemical compound C([C@H]1CC2)[C@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@@H](CCC(O)=O)C)[C@@]2(C)[C@@H](O)C1 KXGVEGMKQFWNSR-LLQZFEROSA-N 0.000 description 1
229960003964 deoxycholic acid Drugs 0.000 description 1
238000001514 detection method Methods 0.000 description 1
239000003599 detergent Substances 0.000 description 1
229940079593 drug Drugs 0.000 description 1
239000003814 drug Substances 0.000 description 1
229940088598 enzyme Drugs 0.000 description 1
150000002148 esters Chemical class 0.000 description 1
150000002170 ethers Chemical class 0.000 description 1
238000002474 experimental method Methods 0.000 description 1
229950003499 fibrin Drugs 0.000 description 1
229940012952 fibrinogen Drugs 0.000 description 1
229940044170 formate Drugs 0.000 description 1
235000019253 formic acid Nutrition 0.000 description 1
BTCSSZJGUNDROE-UHFFFAOYSA-N gamma-aminobutyric acid Chemical compound NCCCC(O)=O BTCSSZJGUNDROE-UHFFFAOYSA-N 0.000 description 1
230000023597 hemostasis Effects 0.000 description 1
230000002209 hydrophobic effect Effects 0.000 description 1
238000002955 isolation Methods 0.000 description 1
238000002386 leaching Methods 0.000 description 1
239000007788 liquid Substances 0.000 description 1
238000002156 mixing Methods 0.000 description 1
239000000203 mixture Substances 0.000 description 1
231100000915 pathological change Toxicity 0.000 description 1
230000036285 pathological change Effects 0.000 description 1
239000013610 patient sample Substances 0.000 description 1
239000000546 pharmaceutical excipient Substances 0.000 description 1
238000000053 physical method Methods 0.000 description 1
239000002504 physiological saline solution Substances 0.000 description 1
230000002035 prolonged effect Effects 0.000 description 1
238000011084 recovery Methods 0.000 description 1
238000000926 separation method Methods 0.000 description 1
229910052708 sodium Inorganic materials 0.000 description 1
239000011734 sodium Substances 0.000 description 1
239000011780 sodium chloride Substances 0.000 description 1
238000001179 sorption measurement Methods 0.000 description 1
230000009469 supplementation Effects 0.000 description 1
230000001502 supplementing effect Effects 0.000 description 1
238000002560 therapeutic procedure Methods 0.000 description 1
RTKIYNMVFMVABJ-UHFFFAOYSA-L thimerosal Chemical compound [Na+].CC[Hg]SC1=CC=CC=C1C([O-])=O RTKIYNMVFMVABJ-UHFFFAOYSA-L 0.000 description 1
230000001026 thromboplastic effect Effects 0.000 description 1
231100000732 tissue residue Toxicity 0.000 description 1
238000011144 upstream manufacturing Methods 0.000 description 1
230000002792 vascular Effects 0.000 description 1
208000030401 vitamin deficiency disease Diseases 0.000 description 1

Classifications

- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/56—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving blood clotting factors, e.g. involving thrombin, thromboplastin, fibrinogen
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/745—Blood coagulation or fibrinolysis factors
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/745—Assays involving non-enzymic blood coagulation factors
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10S530/00—Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof
- Y10S530/827—Proteins from mammals or birds
- Y10S530/839—Nerves; brain

Landscapes

Chemical & Material Sciences (AREA)
Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Organic Chemistry (AREA)
Zoology (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Engineering & Computer Science (AREA)
Hematology (AREA)
Biophysics (AREA)
General Health & Medical Sciences (AREA)
Genetics & Genomics (AREA)
Wood Science & Technology (AREA)
Molecular Biology (AREA)
Biochemistry (AREA)
Microbiology (AREA)
Physics & Mathematics (AREA)
Analytical Chemistry (AREA)
Toxicology (AREA)
Biotechnology (AREA)
Immunology (AREA)
Gastroenterology & Hepatology (AREA)
Medicinal Chemistry (AREA)
Bioinformatics & Cheminformatics (AREA)
General Engineering & Computer Science (AREA)
Neurosurgery (AREA)
Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Investigating Or Analysing Biological Materials (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Saccharide Compounds (AREA)
Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
Lubricants (AREA)
Transition And Organic Metals Composition Catalysts For Addition Polymerization (AREA)
Coloring Foods And Improving Nutritive Qualities (AREA)
Measurement Of The Respiration, Hearing Ability, Form, And Blood Characteristics Of Living Organisms (AREA)
Materials For Medical Uses (AREA)

DD82246077A 1981-12-21 1982-12-16 Verfahren zur herstellung von gewebsthromboplastin DD208811A5 (de)

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
DE19813150596 DE3150596A1 (de)	1981-12-21	1981-12-21	Verfahren zur herstellung von gewebsthromboplastin

Publications (1)

Publication Number	Publication Date
DD208811A5 true DD208811A5 (de)	1984-04-11

Family

ID=6149306

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
DD82246077A DD208811A5 (de)	1981-12-21	1982-12-16	Verfahren zur herstellung von gewebsthromboplastin

Country Status (11)

Country	Link
US (1)	US4416812A (da)
EP (1)	EP0083773B1 (da)
JP (1)	JPS58154515A (da)
AT (1)	ATE13447T1 (da)
CA (1)	CA1195614A (da)
DD (1)	DD208811A5 (da)
DE (2)	DE3150596A1 (da)
DK (1)	DK158474C (da)
ES (1)	ES8402942A1 (da)
NO (1)	NO160747C (da)
ZA (1)	ZA829315B (da)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US4928603A (en) *	1984-09-07	1990-05-29	The Trustees Of Columbia University In The City Of New York	Method of preparing a cryoprecipitated suspension and use thereof
US4755461A (en) *	1986-04-17	1988-07-05	Bio/Data Corporation	Tableted blood plasma microconcentrated thromboplastin coagulation reagent
US5017556A (en) *	1986-11-04	1991-05-21	Genentech, Inc.	Treatment of bleeding disorders using lipid-free tissue factor protein
ES2073391T3 (es) *	1986-11-04	1995-08-16	Genentech Inc	Metodo y composiciones terapeuticas para el tratamiento de trastornos de perdidas de sangre.
US5589173A (en)	1986-11-04	1996-12-31	Genentech, Inc.	Method and therapeutic compositions for the treatment of myocardial infarction
US5270451A (en) *	1988-11-23	1993-12-14	Baxter Diagnostics Inc.	Extraction method for preparing thromboplastin reagents
US5281528A (en) *	1989-12-18	1994-01-25	Warner-Lambert Company	Process for purified thromboplastin for ultra-pure thrombin preparation
US5254350A (en) *	1991-07-22	1993-10-19	Helena Laboratories Corporation	Method of preparing a thromboplastin extract
JP3180824B2 (ja) *	1991-08-30	2001-06-25	シスメックス株式会社	血液凝固試薬
CA2080428C (en) *	1991-10-22	2004-01-27	Ray F. Ebert	A method for preparing a thromboplastin reagent from cultured cells that is suitable for use in the prothrombin time test
US5358853A (en) *	1992-08-03	1994-10-25	Akzo Av	Liquid thromboplastin reagent
US5418141A (en) *	1994-05-06	1995-05-23	Avocet Medical, Inc.	Test articles for performing dry reagent prothrombin time assays
DE19538716A1 (de) *	1995-10-18	1997-04-24	Behringwerke Ag	Verfahren zur Quantifizierung von aktiviertem Gerinnungsfaktor VII (FVIIa)
DE19538715A1 (de)	1995-10-18	1997-04-30	Behringwerke Ag	Verfahren zur Reinigung von Faktor VII und aktiviertem Faktor VII
NL1008674C2 (nl) *	1998-03-23	1999-09-24	Harimex Bv	Werkwijze voor het bereiden van tromboplastine uit dierlijk weefsel.
JP2002526557A (ja)	1998-10-07	2002-08-20	シグマ−アルドリッチ・カンパニー	トロンボプラスチン試薬ならびにそのような試薬の製造および使用方法
US6183979B1 (en) *	1999-03-24	2001-02-06	International Technidyne Corporation	Preparation of dried synthetic prothrombin time reagents
JP4526152B2 (ja) *	2000-03-08	2010-08-18	シスメックス株式会社	プロトロンビン時間測定試薬
GB0327094D0 (en) *	2003-11-21	2003-12-24	Inverness Medical Switzerland	Laminated device
US7148067B2 (en) *	2004-08-31	2006-12-12	The Board Of Trustees Of The University Of Illinois	Thromboplastin reagents
US20080260858A1 (en) *	2005-02-16	2008-10-23	The Board Of Trustees Of The University Of Illnois	Universal Procoagulant
EP1869082B1 (en) *	2005-03-04	2011-04-13	The Board Of Trustees Of The University Of Illinois	Coagulation and fibrinolytic cascades modulator
WO2009046194A2 (en) *	2007-10-05	2009-04-09	The Board Of Trustees Of The University Of Illinois	Fibrin sealant
US20100297257A1 (en) *	2007-11-09	2010-11-25	National Institutes Of Health (Nih), U.S. Dept. Of Health And Human Services (Dhhs)	Anticoagulant antagonist and hemophillia procoagulant
DE102007062323A1 (de) *	2007-12-21	2009-06-25	Siemens Healthcare Diagnostics Products Gmbh	Langzeitstabiles Thromboplastin-Reagenz
EP2405274A1 (en)	2010-07-06	2012-01-11	Good biomarker Sciences B.V.	Monitoring anticoagulant therapy and identifying reversible direct factor Xa inhibitors

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US2842480A (en) *	1954-05-27	1958-07-08	Ortho Pharma Corp	Preparation of thromboplastin
US2847348A (en) *	1954-05-27	1958-08-12	Ortho Pharma Corp	Plasma fractionation and product therefrom
US2847350A (en) *	1954-05-27	1958-08-12	Ortho Pharma Corp	Preparation of highly active thromboplastin
US2921000A (en) *	1956-05-22	1960-01-12	Ortho Pharma Corp	Thromboplastin
NL238873A (da) *	1958-05-16
US3228841A (en) *	1965-06-10	1966-01-11	Warner Lambert Pharmaceutical	Diagnostic reagent composition for determining blood coagulation factors and method of use
US3522148A (en) *	1965-08-13	1970-07-28	Dade Reagents Inc	Stabilized thromboplastin preparation
US3980432A (en) *	1973-04-02	1976-09-14	Behringwerke Aktiengesellschaft	Partial thromboplastin, its use as diagnostic agent and process for preparing it
ES431736A1 (es) *	1973-11-13	1977-05-16	Behringwerke Ag	Procedimiento para la preparacion de un agente para diagnos-tico para el proposito de efectuar el control de la capaci- dad de coagulacion de la sangre.

1981
- 1981-12-21 DE DE19813150596 patent/DE3150596A1/de not_active Withdrawn
1982
- 1982-12-01 US US06/446,088 patent/US4416812A/en not_active Expired - Lifetime
- 1982-12-06 DK DK540082A patent/DK158474C/da not_active IP Right Cessation
- 1982-12-14 CA CA000417627A patent/CA1195614A/en not_active Expired
- 1982-12-16 DD DD82246077A patent/DD208811A5/de not_active IP Right Cessation
- 1982-12-20 NO NO824279A patent/NO160747C/no not_active IP Right Cessation
- 1982-12-20 EP EP82111801A patent/EP0083773B1/de not_active Expired
- 1982-12-20 ZA ZA829315A patent/ZA829315B/xx unknown
- 1982-12-20 DE DE8282111801T patent/DE3263793D1/de not_active Expired
- 1982-12-20 AT AT82111801T patent/ATE13447T1/de not_active IP Right Cessation
- 1982-12-20 JP JP57222215A patent/JPS58154515A/ja active Granted
- 1982-12-21 ES ES518420A patent/ES8402942A1/es not_active Expired

Also Published As

Publication number	Publication date
ES518420A0 (es)	1984-03-01
CA1195614A (en)	1985-10-22
EP0083773A1 (de)	1983-07-20
DE3263793D1 (en)	1985-06-27
DE3150596A1 (de)	1983-06-30
US4416812A (en)	1983-11-22
DK158474B (da)	1990-05-21
JPS58154515A (ja)	1983-09-14
EP0083773B1 (de)	1985-05-22
NO160747C (no)	1989-05-24
DK540082A (da)	1983-06-22
NO160747B (no)	1989-02-13
JPH0339267B2 (da)	1991-06-13
ATE13447T1 (de)	1985-06-15
ZA829315B (en)	1983-10-26
ES8402942A1 (es)	1984-03-01
DK158474C (da)	1990-10-15
NO824279L (no)	1983-06-22

Legal Events

Date	Code	Title	Description
1999-10-14	ENJ	Ceased due to non-payment of renewal fee

Publication	Publication Date	Title
EP0083773B1 (de)	1985-05-22	Verfahren zur Herstellung eines Gewebsthromboplastinpräparates
EP0244834B1 (de)	1992-03-18	Verfahren zur Herstellung eines Faktor V-Konzentrats
DE69033033T2 (de)	1999-10-28	Verbesserte kontrollverfahren für stabile blutkoagulation
DE2619667C2 (de)	1984-12-06	Pharmazeutisches Mittel
DE2546166A1 (de)	1977-04-28	Gegerbte thrombozyten
EP0049877B1 (de)	1984-05-23	Verfahren und Reagenz zur Bestimmung von Antithrombin-BM
DE68912115T2 (de)	1994-08-11	Ausscheidungsverfahren für die herstellung von thromboplastinreagenzien.
EP0018353A1 (de)	1980-10-29	Verfahren zur Herstellung von nebenwirkungsfreien Plasmafraktionen
EP0023607A2 (de)	1981-02-11	Verfahren zur Herstellung einer Kollagenlösung, eine solche Lösung sowie ihre Verwendung
EP0003474B1 (de)	1981-11-25	Verfahren zur Prothrombin-Bestimmung, dazu verwendetes Reagenz und Verfahren zur Herstellung eines Faktor-Xa-Präparats
EP0062310B1 (de)	1985-12-11	Reagens zur optischen Bestimmung des Blutgerinnungsverhaltens
EP0189910B1 (de)	1989-08-23	Verfahren zur Bestimmung des fibrinolytischen Zustands von Plasma
EP0120220A2 (de)	1984-10-03	Verfahren und Reagenz zur Glucosebestimmung im hämolysierten Blut
DE69230209T2 (de)	2000-03-23	Reagenz zur Blutgerinnung
DE2654189C3 (de)	1985-10-03	Verfahren zur in-vitro-Bestimmung der biologischen Aktivität von Faktor Xa-Inhibitor im Blut
DE68912477T3 (de)	1999-12-23	Verfahren zum messen der biologischen wirkung von antithrombin iii und reagenzkit zu dessen messung
DE69016858T2 (de)	1995-06-08	Verfahren und Reagenziensatz zur Bestimmung der funktionalen Aktivität von Protein S in menschlichem Plasma.
EP0570356B1 (de)	1999-02-17	Reagens zur Bestimmung der aktivierten partiellen Thromboplastinzeit (aPTT)
EP0570354B1 (de)	1998-09-02	Verfahren zur Bestimmung von Fibrinogen
EP0020895A1 (de)	1981-01-07	Partielles Thromboplastin
EP0182929A1 (de)	1986-06-04	Koaktivator zur Aktivierung von Protein C
DE2902657A1 (de)	1979-07-26	Verfahren zur herstellung von den gerinnungsfaktor ii, v oder viii oder deren gemische enthaltenden konzentraten oder von den faktoren vii, ix, x, xi oder xii oder den gemischen freiem plasma
AT403437B (de)	1998-02-25	Physiologisch aktive gewebefaktor-präparation
DE3707213A1 (de)	1988-09-15	Verfahren zur herstellung von faktor viii:c-mangelplasma und ein so erhaltenes mangelplasma
EP4394045B1 (de)	2025-07-09	Verfahren zur bestimmung von fibrinogen